Spesolimab 450mg/7.5ml solution for infusion vials

BackgroundPyoderma gangrenosum (PG) is a rare disease causing painful skin ulcers, typically starting with tender pustules that quickly develop into painful ulcers. Traditional treatments like glucocorticoids and immunosuppressants often have adverse effects and limited efficacy, making them unsuitable for all patients. Recent evidence shows that biological agents are more effective and safer, leading to increased acceptance. However, selecting the most suitable biological agent from the many available options remains a significant challenge for both physicians and patients.ObjectiveTo systematically review the treatment outcomes of two biologics: TNF (tumour necrosis factors)-α inhibitors and IL (interleukin) inhibitors in pyoderma gangrenosum.MethodsA search of Pubmed was conducted on September 7, 2024. A total of 107 studies were included using Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines.ResultsA total of 139 patients were included. Ninety-two were treated with TNF-α inhibitors and 47 with IL inhibitors. The number of included cases and the efficacy are Infliximab (n=52, 88.4%), Adalimumab (n=23, 91.3%), Etanercept (n=13, 84.6%), Certolizumab (n=3, 66.6%), Golimumab (n=1, 100.0%), Anakinra (n=11, 100.0%), Canakinumab (n=7, 100.0%), Secukinumab (n=5, 40.0%), Brodalumab (n=3, 100.0%), Ixekizumab (n=1, 100.0%), Ustekinumab (n=12, 100.0%), Spesolimab (n=3, 100.0%), Guselkumab (n=2, 100.0%), Tildrakizumab (n=2, 100.0%), Risankizuma (n=1, 100.0%). Among them, 46.0% (n=64) achieved complete remission, including 47 (33.8%) who used TNF-α inhibitors and 17 (12.2%) with IL inhibitors. And the total effective rate of IL- inhibitors (93.6%) was higher than that of TNF-α inhibitors (88.0%), but had no statistical significance (p>0.05). However, it takes less time for IL inhibitors to reach partial remission or complete remission. Additionally, in infliximab group, the number of adverse events that occurred was large and varied.ConclusionDifference in effective rate shows no statistical significance between two kinds of agents. However, IL inhibitors demonstrate an advantage with shorter treatment cycles. Additionally, Infliximab has a wider range of side effects and should be used with caution.PROSPERO number: CRD42024608039.

Abstract licence: CC BY-NC

Sir, Generalized pustular psoriasis (GPP) is a severe and potentially fatal condition that is distinguished by the emergence of pustular lesions throughout the body.[1] This condition is challenging to treat because of its slow progression. Researchers have investigated this disease because of its unclear causes and progression. Interleukin 36 (IL-36) is a critical component of the process of inflammation, and its dysregulation can exacerbate this condition over time.[2] Recently, drugs have been developed to block the IL-36 receptor, marking a new era in its treatment. In 2021, the anti-IL-36 receptor antibody spesolimab showed promising results in the rapid and efficient resolution of pustular lesions.[3,4] However, safety concerns have also been raised, making it necessary to cautiously discuss its potential use. A clinical trial conducted by Mrowietz et al. evaluated the effectiveness and safety of spesolimab in 59 individuals with palmoplantar pustulosis (PPP) divided into three groups receiving placebo, 300 mg, or 900 mg of the drug every 4 weeks for 12 weeks.[4] The PPP Area and Severity Index 50 was used to assess efficacy, with a 50% reduction in the baseline score considered statistically significant. While both the intervention (31.6%) and placebo (23.8%) groups significantly reduced their index at week 16, the results did not meet the target risk difference of 0.078 (95% confidence interval, −0.190–0.338). This study found that spesolimab improved the disease severity index, but not as expected, and some individuals may have had a bias in lesion resolution coinciding with the natural history of the disease.[4] However, Bachelez et al. conducted a phase II study with only two groups, comprising 900 mg (n = 35) and placebo (n = 18), to evaluate the safety and efficacy of spesolimab for the treatment of GPP.[3] The primary objective was a considerable decrease in the GPP Physician Global Assessment (GPPGA) score, which ranged from 0 (no injuries) to 4 (serious injuries). In the initial stages of the trial, 46% of the individuals in the spesolimab group and 39% in the placebo group had scores of 3 and 4, respectively. In the 1st week of the trial, 54% of the individuals in the intervention group had a GGPGA score of 0, whereas only 6% of the control group achieved the same score. By the end of the trial, 43% of individuals in the spesolimab group (n = 15/35) had a score of 0 or 1, compared to 11% of the placebo group individuals (n = 2/35). The safety profile observed in this study is noteworthy. Two individuals in the spesolimab group experienced adverse reactions to the medication, and 47% of the same group experienced some form of infection compared to 17% in the placebo group. These mixed results raise the question of whether spesolimab is worthy of use. While significant improvements were observed in the GGPGA score in both the 1st and last weeks of the trial, the development of antibodies may account for the occurrence of adverse reactions, which did not result in death.[3] Baum et al. assessed the regulation of signaling pathways that play a role in the GPP inflammatory process, including IL-36.[2] The authors examined the molecular profiles of damaged skin tissue and did not compare the regulation in individuals with PPP (n = 8) or PPG (n = 7) with that in healthy individuals (n = 16).[2] Samples were obtained both before and after treatment to assess immunohistochemistry, histology, and ribonucleic acid sequencing. The study found 1287 transcript variations in individuals with untreated PPP or GPP, with an increasing trend in signaling pathways related to IL-36. In contrast, pro-inflammatory proteins, innate inflammation signaling, neutrophilic mediators, and other biomarkers or skin cell groups associated with the inflammatory process are all downregulated in individuals treated with these conditions.[2] Therefore, biological plausibility exists between the molecular foundations that led to the production of this medication and the clinical results obtained in these studies. However, the small sample size used in the study compromised the internal and external validity of the findings.[2,3] Given these limitations, it does not seem prudent to use spesolimab at this time, especially in individuals with comorbidities where adverse events may be more severe. Further studies with larger sample sizes are needed to better understand the risk–benefit ratio and prioritize patient safety. Financial support and sponsorship Nil. Conflicts of interest There are no conflicts of interest.

Abstract licence: CC BY-NC-SA 4.0